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Introduction
Adhesive bowel obstruction (ABO) is blockade of  luminal 
flow of  bowel content due to trapping or entanglement of  
bowel loops by fibrous or fibrinous bands between peritoneal 
surfaces1,2. It is the leading cause of  intestinal obstruction 
(IO) in developed countries and it is overtaking strangulated 
hernia as the most common cause of  IO in developing 
countries3-9. ABO is the most common general surgical 
complication of  intra-abdominal adhesions necessitating re-
admission and surgical intervention10,11. Other complications 
of  intra-abdominal adhesions are chronic pain and 
infertility10. Unlike strangulated hernia, ABO is difficult 
to diagnose and decision making on whether to proceed 
to operative management (OM) or attempt non-operative 
management(NOM) is more challenging11,12. The difficulties 
in decision making cause high morbidity and exorbitant cost 
of  treatment13.
Deficit of  knowledge about management of  ABO raises 
controversies regarding the best method of  diagnosis, 
decision making on immediate OM or trial of  NOM and 
the most appropriate duration of  trial of  nonoperative 
management (dNOM)2,3,13-16. The difficulties in decision 
making escalate the overall cost of  management, contribute 
to poor outcome and increase the suffering felt by patients10.
The monetary implication of  surgical intervention and 
hospitalization for ABO was estimated at $1.3billion/year in 
the United States of  America in 199411. A more recent report 
estimates the cost at $2 billion/year1,11,17. The monetary 
implication of  management of  ABO is unknown in 
developing centers. The escalating cost of  ABO management 
is related to duration of  admission and re-admission, and the 
morbidity of  delayed OM or inappropriate OM. The aim of  
this study was to describe the cost of  management decisions, 
specifically, the cost effectiveness of  various duration of  
NOM among patients who presented with ABO in a poor 
resource center in order to facilitate management decision 
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Adhesive bowel obstruction (ABO) costs billions of  dollars in developed countries. Cost is unknown in developing 
countries. This depends on the type of  management and duration of  hospital stay. Nonoperative management (NOM) 
of  uncomplicated obstruction is safe for up to 10 days. While it remains cost effective, the most efficient duration of  
nonoperative management must retain its advantages over operative management. 
Aim
To describe cost effectiveness of  various durations of  nonoperative management of  adhesive obstruction in a developing 
country. 
Method
Over 2 year period, Patients who had uncomplicated adhesive obstruction were observed on trial of  nonoperative 
management. Length of  hospital stay and success rate were combined as surrogates for Cost effectiveness analysis of  2 to 
5 days and ≥7 days nonoperative management. 
Results
41 patients (24(58.5%) females) were eligible. Mean age 38.4 ± 14.7 (range 18-80) years. 31 (75.6%) were first time admissions. 
The most common previous abdominal operations were for appendix and obstetrics and gynecologic pathologies. Median 
duration of  nonoperative management (dNOM) was 4 days, median LOS was 9 days. Nonoperative management was 
successful in 53.7% (22 patients). Total estimated direct hospital cost of  41 adhesive bowel obstructions was $133,279. 
Total personnel charges were $112,142. Mean operative and nonoperative management was $4,914 and $1,814 respectively 
(p <0.0001). Most of  successful nonoperative management was within 5 days. 4 days nonoperative management had the 
highest cost utility.
Conclusion 
From this study, without indications for immediate surgical intervention, 4 days nonoperative management is the most cost 
effective course, after which surgical intervention may be considered if  there is no improvement.  
policies in such patients 
Method
This was a prospective cross-sectional study conducted in 
a government owned tertiary hospital, namely the General 
Surgery Division of  the University of  Ilorin Teaching 
Hospital, northcentral Nigeria between December 2013 
and November 2015. After due ethical clearance, patients 
with provisional diagnosis of  ABO were included. Patient 
requiring immediate OM and those whose final diagnosis 
was not ABO were excluded. 
At the time of  this study, the clinical evaluation for fitness 
for NOM was augmented by plain abdominal X-ray and 
ultrasound findings. While preference was given to the 
clinical abdominal examination findings in decision making 
about patient inclusion, the nonspecific vital signs influenced 
exclusion; patients whose systolic blood pressure was 
lower than 100mmhg, whose pulse was persistently higher 
than 100bpm and whose temperature was higher than 
38.00C after initial resuscitation, were excluded. The NOM 
included nasogastric intubation, intravenous nutritional 
supplementation via peripheral venous access and close 
observation of  clinical features. There was no consensus yet in 
the centre about the duration of  non-operative management 
(dNOM). Success of  NOM was based on return of  normal 
bowel functions. dNOM was time to discontinuation of  
suck and drip and commencement of  oral feeding or time to 
decision for surgical intervention. 
Variables of  interest were patients’ demographics, symptoms 
at presentation, type of  previous abdominal operation(s), and 
dNOM. The length of  hospital stay (LOS) and success rate 
of  NOM (srNOM) were the primary measures of  outcome. 
Working with the objective that our management decision 
was to achieve the highest possible success rate in the shortest 
duration of  admission, the LOS and srNOM were combined 
as surrogates for estimating benefit in the cost effectiveness 
analysis (CEA) by finding the product of  inverse of  median 
LOS and srNOM [benefit =1/(LOS_median)×srNOM]. 
Cost of  treatment was estimated using the resource unit unit 
(RUU) applied to a simple predictable model of  trajectory 
through the hospital service.
The model of  trajectory of  care was constructed starting 
from the emergency room care to the admission ward (via 
operating theater in the operative group) and to discharge 
from inpatient care. The personnel involved in patient care, 
intravenous fluid and nutritional supplementation, laboratory 
investigations and the medications were standardized with 
an assumption of  uniform homogenous requirement and 
trajectory of  care within the separate groups. 
The daily wages of  the personnel were derived from the 
monthly gross emolument of  each cadre. The daily cost 
of  intravenous fluid supplementation and nutritional 
supplementation was estimated from simple mathematical 
addition of  the cost of  intravenous fluid, intravenous 
supplementation of  vitamin B-complex, vitamin C, vitamin 
E, vitamin K and intravenous magnesium-sulphate based on 
the standard daily requirement which was the protocol for 
suck and  drip  in the general surgery division at the time of  the 
study. The cost of  laboratory requirement was the exact cost 
of  investigation in the hospital at the time of  the study. The 
total cost of  investigation for each patient was dependent on 
the count of  orders made during the duration of  admission. 
It was assumed that each patient required only the services 
of  the direct primary care personnel per day except when 
operated upon (see table 1). The scope of  data collection 
for each patient and the costing for each patient ended upon 
discharge from admission for the index presentation. The 
complications necessitating prolonged admission was not 
specifically sought because of  the prior assumption that 
the reason for short or long admission was a function of  
our decision to delay immediate operative intervention 
i.e. a form of  intention to treat analysis. The indirect and 
intangible costs were excluded because they were difficult 
to standardize for measurement and extremely variable 
thus might introduce bias in costing. Cost was expressed 
in monetary value using the United States Dollars(USD) at 
the time of  the study, and official equivalent of  1 dollar was 
198 Nigerian Naira. The costing method used was macro-
costing rather than activity based because the assumptions 
of  this study were based on predictable trajectory of  care. 
Also, because the primary measure of  outcome was variation 
in days of  admission rather than events within the day, the 
macro-costing was considered sufficient rather than micro-
costing.
The CEA of  2,3,4,5 and ≥7 days dNOM were estimated 
and incremental cost effectiveness ratios (ICER) compared 
Figure 1: Flow diagram of patient selection 
Table 1: Estimates of Resource Unit Use charges
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Discussion
When there are competing options, the most cost effective 
among viable alternatives will to be preferred  especially in 
a climate of  limited resources. If  the provisional clinical 
diagnosis of  intestinal obstruction is ABO and the patient 
shows no signs of  bowel strangulation or other complications, 
trial of  NOM is safe3,11,15. The best duration of  NOM before 
instituting surgical intervention is debatable3.  One important 
point to remember is that the most efficient duration of  
NOM must sustain the advantages of  NOM over OM by 
preventing inadvertent unnecessary suffering and at the 
same time remain cost effective. 
The aim of  this study was to describe the cost effectiveness 
of  various duration of  NOM before opting for operative 
management in a patient with ABO. 41 patients were 
managed by initial trial of  NOM in a resource poor centre. 
There were more females than males in tandem with 
previous reports3,18. Also in tandem with previous reports, 
the most frequent causes of  ABO were abdominal surgeries 
for appendicular pathologies and obstetrics or gynecologic 
conditions3,19. Abdominal pain (100%), vomiting (95%) and 
abdominal tenderness (80%) were the most frequent clinical 
findings also in conformity with previous reports. About 
54% of  the ABOs were successful on NOM. Majority of  
the success was recorded within 5 days of  NOM. In a report 
by Lawal et al7 in Nigeria, there was failed NOM in about 
85% of  patients, necessitating operative intervention. This 
was higher than the rate of  failures recorded in this study. 
Mortality rate in the Lawal et al study was about 6%, while in 
this study, there was no mortality. 
The overall cost of  treatment was about $134,000 for 
treatment of  41 patients with ABO in the study centre. The 
highest cost of  treatment was incurred on personnel charges 
which accounted for about more than two-thirds of   the 
direct hospital charges in a government owned not for profit 
hospital. 
where appropriate. The CEA of  3 days dNOM preferred in 
the Bologna guideline2 was taken as the status quo. A one-
tailed exploratory analysis at 99% confidence interval was 
performed to compare the cost of  NOM and OM. Statistical 
analysis and graphical presentations were produced using 
SPSS v16 and R-statistical package version 3.2.2. 
Results
41 patients fit the eligibility criteria over a 2 year study 
period (figure1). There were 17 males and 24 females. The 
age range was 18-80 years (38.4 ± 14.7). 30 patients were 
first time admissions for ABO, 9 were second time and 2 
were third time admissions. The most common indication 
for the previous abdominal operations was appendicular 
pathology (table 2). The median interval between the ultimate 
abdominal operation and the index ABO was 18 months 
(table 2). All patients had abdominal pain at presentation. 
Other symptoms were vomiting, constipation, distension 
and fever (figure 2). 
The total cost of  managing 41 patients was $133,279. The 
personnel charges accounted for $112,142(84.1%). The RUU 
charges are shown in table 1 . The maximum and minimum 
cost for NOM and OM were $794 and 3,641, and $1,126 
and $10,243, respectively. The mean cost of  OM was $4,914, 
while the mean cost of  NOM was $1,814. The total cost of  
NOM in 22 patients was $39,924, while the total OM for 19 
patients was $93,356. The exploratory one-tail t-test at 99% 
confidence limits hypothesizing that the cost of  OM was 
higher than the cost NOM returned p value < 0.0001. There 
was a direct relationship between duration of  suck and drip 
and cost of  treatment (figure 3).
All patients were commenced on initial trial of  NOM. 
OM was instituted after failure of  NOM. All patients were 
managed and discharged. There was no mortality. Most of  
the success recorded on NOM was within 5 days, and the rate 
of  successful NOM was 53.7%. The benefit of  3 dNOM, 
which was considered the status quo for ICER analysis, 
was 5.9. The 4 days NOM had the highest benefit. From 3 
dNOM to 4 dNOM, 4 additional patients were successfully 
managed non-operatively at ICER of  USD 246 (table 3).
As expected, in the exploratory analysis, the cost of  treatment 
for patients who had OM was significantly higher than those 
who were successfully managed by NOM. There was a direct 
relationship between cost of  treatment and the duration of  
suck and drip irrespective of  the outcome of  NOM (figure 
2). The cost of  OM could have been escalated because all 
patients had initial trial of  NOM. This implies that if  we can 
select patients who are unlikely to succeed on NOM, then 
early OM should minimize their overall cost of  treatment. 
So, research describing methods of  accurately identifying 
patients unlikely to benefit from NOM are required.
If  there are no reasons for immediate surgical intervention, 
continuing NOM for 4 days, after which OM should be 
considered if  there is no significant improvement, was 
found to be the most cost effective course of  action. The 
cost utility analysis showed that for an additional day of  
dNOM beyond 3 days, the benefit score was higher and 
an additional 4 successes were recorded at about $62 extra 
cost per success. Compared to the status quo, the 5 dNOM 
also had higher benefit score and additional 10 successes 
for additional 2 days beyond 3 days of  NOM. However, the 
5dNOM compared unfavorably with the 4 dNOM.
It is important to discuss limitations of  this study as will be 
expected for studies on economic analysis. To start with, we 
assumed homogeneity of  illness progression and course of  
treatment. We also assumed that the length of  hospital stay 
is directly related to the morbidity and cost of  treatment. 
Hence, the effectiveness of  NOM was estimated by simple 
mathematical combination of  endpoints, namely the LOS 
and the srNOM. These endpoints are intermediate endpoints 
limited to the outcome of  index admission in contrast to 
the commonly used measures such as quality adjusted life 
years (QALY) which considers the effect of  the intervention 
beyond the current intervention and over the duration of  
continued existence of  patients.  
Although we have found 4 dNOM to be most cost effective, 
interpretation of  finding on economic analysis should not be 
in a vacuum. It should depend on the costing method, the 
context of  analysis and the limits of  willingness to spend. 
Finally, the cost of  managing ABO can be highly variable. 
The costing method in this study employed the less stringent 
and rather narrower macro-costing of  the direct hospital 
charges, excluding the indirect hospital charges and the non-
hospital and intangible charges. 
Conclusion
With respect to the management of  an index admission 
only, when there are no reasons for immediate surgical 
intervention, continuing NOM for 4 days, after which OM 
should be considered if  there is no significant improvement, 
was found to be the most cost effective course of  action in 
this study. 
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